Bristol-Myers Squibb Company
$59.38
▼
-0.02%
2026-04-22 10:12:13
www.bms.com
NYQ: BMY
Explore Bristol-Myers Squibb Company stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$121.36 B
Current Price
$59.38
52W High / Low
$62.89 / $42.52
Stock P/E
17.16
Book Value
$9.07
Dividend Yield
4.26%
ROCE
20.6%
ROE
40.44%
Face Value
—
EPS
$3.46
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
32,500
Beta
0.27
Debt / Equity
254.98
Current Ratio
1.25
Quick Ratio
1.14
Forward P/E
9.52
Price / Sales
2.48
Enterprise Value
$155.93 B
EV / EBITDA
8.16
EV / Revenue
3.23
Rating
Hold
Target Price
$63.04
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
- Meaningful dividend yield is available.
Cons
- Leverage is relatively high.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Biogen Inc. | $191.44 | 21.83 | $28.09 B | — | 9.46% | 7.39% | $202.41 / $114.66 | $124.36 |
| 2. | Organon & Co. | $9.26 | 12.89 | $2.41 B | 0.86% | 11.7% | 30.56% | $13.24 / $5.69 | $2.89 |
| 3. | Pfizer Inc. | $26.9 | 19.83 | $152.79 B | 6.25% | 10.17% | 8.89% | $28.75 / $21.87 | $15.21 |
| 4. | Nasus Pharma Ltd. | $2.86 | — | $19.29 M | — | -172.62% | 2637.84% | $9.99 / $1.98 | $0.31 |
| 5. | Amgen Inc. | $346.69 | 24.37 | $187.08 B | 2.84% | 13.95% | 1.06% | $391.29 / $261.43 | $16.07 |
| 6. | Scilex Holding Company | $6.95 | — | $58.97 M | — | 55.67% | 39.83% | $34.27 / $3.6 | $-29.75 |
| 7. | MIRA Pharmaceuticals, Inc. | $1.12 | — | $47.06 M | — | -100.98% | -1.66% | $2.45 / $0.83 | $0.25 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 12.5 B | 12.22 B | 12.27 B | 11.2 B | 12.34 B | — |
| Operating Profit | 2.81 B | 3.64 B | 3.77 B | 3.5 B | 510 M | — |
| Net Profit | 1.09 B | 2.2 B | 1.31 B | 2.46 B | 72 M | — |
| EPS in Rs | 0.53 | 1.08 | 0.64 | 1.2 | 0.04 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 48.2 B | 48.3 B | 45.01 B | 46.16 B |
| Operating Profit | 13.72 B | 5.89 B | 8.2 B | 9.1 B |
| Net Profit | 7.05 B | -8.95 B | 8.03 B | 6.33 B |
| EPS in Rs | 3.45 | -4.38 | 3.93 | 3.1 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 90.04 B | 92.6 B | 95.16 B | 96.82 B |
| Total Liabilities | 71.53 B | 76.22 B | 65.67 B | 65.7 B |
| Equity | 18.47 B | 16.34 B | 29.43 B | 31.06 B |
| Current Assets | 29.39 B | 29.78 B | 31.77 B | 27.27 B |
| Current Liabilities | 23.42 B | 23.77 B | 22.26 B | 21.89 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 14.16 B | 15.19 B | 13.86 B | 13.07 B |
| Investing CF | -4.13 B | -21.35 B | -2.29 B | -1.06 B |
| Financing CF | -10.35 B | 5.13 B | -9.42 B | -16.96 B |
| Free CF | 12.85 B | 13.94 B | 12.65 B | 11.95 B |
| Capex | -1.31 B | -1.25 B | -1.21 B | -1.12 B |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 7.32% | -2.5% | — | — |
| Earnings Growth % | -211.5% | 26.84% | — | — |
| Profit Margin % | -18.53% | 17.83% | 13.71% | — |
| Operating Margin % | 12.19% | 18.21% | 19.72% | — |
| Gross Margin % | 71.08% | 76.24% | 78.04% | — |
| EBITDA Margin % | 6.56% | 43.03% | 41.64% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-04-02 | $0.63 |
| 2026-01-02 | $0.63 |
| 2025-10-03 | $0.62 |
| 2025-07-03 | $0.62 |
| 2025-04-04 | $0.62 |
Stock Splits
No stock split history available.